ZOMETA® Dosing & Administration For Bone Metastases And Hypercalcaemia (TIH)
Home

Videos
View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

 
European Summary of Product Characteristics
For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics 		 
ZOMETA Dosing & Administration: For Bone Metastases ZOMETA is the current standard of care for the prevention of skeletal-related events (SREs)


      How to use ZOMETA

Dosing for Bone Metastases from solid tumours or osteolytic lesions from multiple myeloma: ZOMETAŽ 4 mg every 3 to 4 weeks Dosing for Tumour-induced Hypercalcaemia (TIH): ZOMETAŽ 4 mg
 
 

Disclaimer: This is an international website for ZOMETA® (zoledronic acid) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US flag at the top right corner of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.

About ZOMETA | ZOMETA Patient Case Studies | ZOMETA Dosing & Administration | ZOMETA Safety & Tolerability | ZOMETA Clinical News | ZOMETA For Your Patients | Professional Resource Center
ZOMETA Around the World

About Novartis OncologySiteMapContactPrivacy
 


Use of this website is subject to our Terms of Use
© 2010 Novartis AG.